E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

NCT03332589 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Single center study: Principal Investigator left institution.

Conditions

Malignant Melanoma
Brain Metastases

Interventions

DRUG: E6201
DRUG: E6201 plus dabrafenib

Sponsor

Spirita Oncology, LLC

Collaborators

[object Object]